BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Many of us have experienced the unpleasant and sometimes embarrassing symptoms of gastrointestinal upset. However, talking ...